Dybly AG

Swiss Biotech Association

Not a member

Dybly develops pharmaceutical products for patients affected by inflammatory and fibrotic diseases. The company owns several molecules with interesting activity and safety profiles. Dybly research is based on a sequence of hypothesis-driven small molecule drug design with validation by empirical data. Our scientific results demonstrate activity in the following pathways: BET-Bromodomain (inhibition); Apo A1 (upregulation); Inflammation (downregulation); Fibrosis (downregulation); Blood cancers: MML and AML (suppression of proliferation)
Indications we are interested in: Fibrotic diseases (lung, liver, heart), Blood cancers, Rheumatoid arthritis and other inflammatory diseases, diseases associated with senescence.

http://www.dybly.com

Location

Bäumleingasse 18, 4051 Basel

Get Directions

Facts & figures

Type of organization

Private company
Year of foundation

2007
Number of employees in Switzerland

1-9

Key business

Core competencies

Therapeutics/vaccines (human)

You may also be interested in

Acthera Therapeutics AG

ACTHERA is a Swiss biotech company and is the result of over 10 years of academic research & development in the universities of Basel, Fribourg and Texas Dallas (USA). The therapeutic platform is based on Hard-Shelled Liposomes (HSLs) that can contain a broad variety of therapeutically active ingredients. ACTHERA’s unique and highly innovative release mechanism will allow the release of active ingredients at therapeutic sites, thus revealing an extraordinarily wide field of applications to transform numerous therapeutic areas.
4052 Basel

Member

Perseo pharma AG

Perseo pharma: best-in-class enzyme therapeutics Perseo pharma is a preclinical-stage biotech start-up developing best-in-class enzyme therapeutics based on an innovative proprietary nanotechnology platform.
4057 Basel

Member

OM Pharma Ltd

OM Pharma is a global Geneva-based Biotech company. It is a leader in the prevention of recurrent respiratory and urinary tract infections and is also active in the treatment of vascular diseases. It operates worldwide through a strong network of international partners and continues to invest into R&D to develop microbial derived immunotherapeutic products addressing acute and chronic immunological disorders resulting from infections and inflammation. OM Pharma is operating to highest Good Manufacturing Practice (GMP) standards which rely on a high level of Biotech competencies and experienced teams. The company strives to help patients around the world to live better lives by allowing access to a better management of infectious diseases and immunological imbalances.
1217 Meyrin

Member